Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
ischemic  ||| S:11 E:20 ||| JJ
postconditioning  ||| S:20 E:37 ||| NN
in  ||| S:37 E:40 ||| IN
patients  ||| S:40 E:49 ||| NNS
with  ||| S:49 E:54 ||| IN
acute  ||| S:54 E:60 ||| JJ
myocardial  ||| S:60 E:71 ||| NNS
infarction  ||| S:71 E:82 ||| VBP
undergoing  ||| S:82 E:93 ||| VBG
primary  ||| S:93 E:101 ||| JJ
PCI ||| S:101 E:104 ||| NNP
:  ||| S:104 E:106 ||| :
a  ||| S:106 E:108 ||| DT
review  ||| S:108 E:115 ||| NN
and  ||| S:115 E:119 ||| CC
meta-analysis  ||| S:119 E:133 ||| JJ
To  ||| S:133 E:136 ||| TO
evaluate  ||| S:136 E:145 ||| VB
the  ||| S:145 E:149 ||| DT
cardiac  ||| S:149 E:157 ||| JJ
protective  ||| S:157 E:168 ||| JJ
effects  ||| S:168 E:176 ||| NNS
of  ||| S:176 E:179 ||| IN
ischemic  ||| S:179 E:188 ||| JJ
postconditioning  ||| S:188 E:205 ||| NNS
( ||| S:205 E:206 ||| -LRB-
IPC ||| S:206 E:209 ||| NNP
)  ||| S:209 E:211 ||| -RRB-
in  ||| S:211 E:214 ||| IN
patients  ||| S:214 E:223 ||| NNS
with  ||| S:223 E:228 ||| IN
acute  ||| S:228 E:234 ||| FW
myocardial  ||| S:234 E:245 ||| FW
infarction  ||| S:245 E:256 ||| FW
( ||| S:256 E:257 ||| -LRB-
AMI ||| S:257 E:260 ||| NNP
)  ||| S:260 E:262 ||| -RRB-
undergoing  ||| S:262 E:273 ||| FW
primary  ||| S:273 E:281 ||| FW
percutaneous  ||| S:281 E:294 ||| FW
coronary  ||| S:294 E:303 ||| FW
intervention  ||| S:303 E:316 ||| FW
( ||| S:316 E:317 ||| -LRB-
PCI ||| S:317 E:320 ||| NNP
) ||| S:320 E:321 ||| -RRB-
.  ||| S:321 E:323 ||| .
Both  ||| S:323 E:328 ||| DT
foreign  ||| S:328 E:336 ||| JJ
and  ||| S:336 E:340 ||| CC
Chinese  ||| S:340 E:348 ||| JJ
databases  ||| S:348 E:358 ||| NNS
including  ||| S:358 E:368 ||| VBG
PubMed ||| S:368 E:374 ||| JJ
,  ||| S:374 E:376 ||| ,
EMbase ||| S:376 E:382 ||| NNP
,  ||| S:382 E:384 ||| ,
Cochrane  ||| S:384 E:393 ||| NNP
library ||| S:393 E:400 ||| NN
,  ||| S:400 E:402 ||| ,
and  ||| S:402 E:406 ||| CC
CNKI  ||| S:406 E:411 ||| NNP
were  ||| S:411 E:416 ||| VBD
searched  ||| S:416 E:425 ||| VBN
to  ||| S:425 E:428 ||| TO
identify  ||| S:428 E:437 ||| VB
randomized  ||| S:437 E:448 ||| VBN
controlled  ||| S:448 E:459 ||| VBN
trials  ||| S:459 E:466 ||| NNS
( ||| S:466 E:467 ||| -LRB-
RCTs ||| S:467 E:471 ||| NNP
)  ||| S:471 E:473 ||| -RRB-
that  ||| S:473 E:478 ||| WDT
reported  ||| S:478 E:487 ||| VBD
the  ||| S:487 E:491 ||| DT
effects  ||| S:491 E:499 ||| NNS
of  ||| S:499 E:502 ||| IN
IPC  ||| S:502 E:506 ||| NNP
on  ||| S:506 E:509 ||| IN
the  ||| S:509 E:513 ||| DT
myocardial  ||| S:513 E:524 ||| JJ
infarction  ||| S:524 E:535 ||| JJ
size ||| S:535 E:539 ||| NN
,  ||| S:539 E:541 ||| ,
myocardial  ||| S:541 E:552 ||| FW
blush  ||| S:552 E:558 ||| FW
grade  ||| S:558 E:564 ||| FW
( ||| S:564 E:565 ||| -LRB-
MBG ||| S:565 E:568 ||| NNP
) ||| S:568 E:569 ||| -RRB-
,  ||| S:569 E:571 ||| ,
left  ||| S:571 E:576 ||| VBD
ventricular  ||| S:576 E:588 ||| JJ
ejection  ||| S:588 E:597 ||| JJ
fraction  ||| S:597 E:606 ||| NN
( ||| S:606 E:607 ||| -LRB-
LVEF ||| S:607 E:611 ||| NNP
)  ||| S:611 E:613 ||| -RRB-
and  ||| S:613 E:617 ||| CC
major  ||| S:617 E:623 ||| JJ
adverse  ||| S:623 E:631 ||| JJ
cardiac  ||| S:631 E:639 ||| JJ
events  ||| S:639 E:646 ||| NNS
( ||| S:646 E:647 ||| -LRB-
MACE ||| S:647 E:651 ||| NNP
) ||| S:651 E:652 ||| -RRB-
.  ||| S:652 E:654 ||| .
Two  ||| S:654 E:658 ||| CD
reviews  ||| S:658 E:666 ||| NNS
assessed  ||| S:666 E:675 ||| VBD
the  ||| S:675 E:679 ||| DT
quality  ||| S:679 E:687 ||| NN
of  ||| S:687 E:690 ||| IN
each  ||| S:690 E:695 ||| DT
trial  ||| S:695 E:701 ||| NN
and  ||| S:701 E:705 ||| CC
extracted  ||| S:705 E:715 ||| JJ
data  ||| S:715 E:720 ||| NNS
independently ||| S:720 E:733 ||| RB
.  ||| S:733 E:735 ||| .
The  ||| S:735 E:739 ||| DT
Cochrane  ||| S:739 E:748 ||| NNP
Collaboration ||| S:748 E:761 ||| NNP
's  ||| S:761 E:764 ||| POS
RevMan  ||| S:764 E:771 ||| JJ
4.2.8  ||| S:771 E:777 ||| CD
software  ||| S:777 E:786 ||| NN
was  ||| S:786 E:790 ||| VBD
used  ||| S:790 E:795 ||| VBN
for  ||| S:795 E:799 ||| IN
statistical  ||| S:799 E:811 ||| JJ
analysis ||| S:811 E:819 ||| NN
.  ||| S:819 E:821 ||| .
Twelve  ||| S:821 E:828 ||| CD
studies  ||| S:828 E:836 ||| NNS
were  ||| S:836 E:841 ||| VBD
identified  ||| S:841 E:852 ||| VBN
and  ||| S:852 E:856 ||| CC
the  ||| S:856 E:860 ||| DT
Meta-analysis  ||| S:860 E:874 ||| NN
included  ||| S:874 E:883 ||| VBD
a  ||| S:883 E:885 ||| DT
total  ||| S:885 E:891 ||| NN
of  ||| S:891 E:894 ||| IN
937  ||| S:894 E:898 ||| CD
patients  ||| S:898 E:907 ||| NNS
with  ||| S:907 E:912 ||| IN
AMI  ||| S:912 E:916 ||| NNP
undergoing  ||| S:916 E:927 ||| VBG
primary  ||| S:927 E:935 ||| JJ
PCI  ||| S:935 E:939 ||| NN
with  ||| S:939 E:944 ||| IN
or  ||| S:944 E:947 ||| CC
without  ||| S:947 E:955 ||| IN
IPC ||| S:955 E:958 ||| NNP
.  ||| S:958 E:960 ||| .
Pooled  ||| S:960 E:967 ||| JJ
analysis  ||| S:967 E:976 ||| NN
of  ||| S:976 E:979 ||| IN
all  ||| S:979 E:983 ||| DT
studies  ||| S:983 E:991 ||| NNS
demonstrated  ||| S:991 E:1004 ||| VBD
no  ||| S:1004 E:1007 ||| DT
significant  ||| S:1007 E:1019 ||| JJ
reductions  ||| S:1019 E:1030 ||| NNS
of  ||| S:1030 E:1033 ||| IN
peak  ||| S:1033 E:1038 ||| JJ
CK  ||| S:1038 E:1041 ||| NNP
and  ||| S:1041 E:1045 ||| CC
CK-MB  ||| S:1045 E:1051 ||| JJ
with  ||| S:1051 E:1056 ||| IN
IPC  ||| S:1056 E:1060 ||| NNP
relative  ||| S:1060 E:1069 ||| JJ
to  ||| S:1069 E:1072 ||| TO
standard  ||| S:1072 E:1081 ||| JJ
care ||| S:1081 E:1085 ||| NN
.  ||| S:1085 E:1087 ||| .
A  ||| S:1087 E:1089 ||| DT
secondary  ||| S:1089 E:1099 ||| JJ
analysis  ||| S:1099 E:1108 ||| NN
of  ||| S:1108 E:1111 ||| IN
the  ||| S:1111 E:1115 ||| DT
studies  ||| S:1115 E:1123 ||| NNS
did ||| S:1123 E:1126 ||| VBD
n't  ||| S:1126 E:1130 ||| RB
show  ||| S:1130 E:1135 ||| VB
improvements  ||| S:1135 E:1148 ||| NNS
of  ||| S:1148 E:1151 ||| IN
left  ||| S:1151 E:1156 ||| VBN
ventricular  ||| S:1156 E:1168 ||| JJ
ejection  ||| S:1168 E:1177 ||| JJ
fraction  ||| S:1177 E:1186 ||| NN
during  ||| S:1186 E:1193 ||| IN
hospitalization  ||| S:1193 E:1209 ||| NN
with  ||| S:1209 E:1214 ||| IN
IPC ||| S:1214 E:1217 ||| NNP
.  ||| S:1217 E:1219 ||| .
However ||| S:1219 E:1226 ||| RB
,  ||| S:1226 E:1228 ||| ,
the  ||| S:1228 E:1232 ||| DT
incidence  ||| S:1232 E:1242 ||| NN
of  ||| S:1242 E:1245 ||| IN
MACE  ||| S:1245 E:1250 ||| NNP
within  ||| S:1250 E:1257 ||| IN
3  ||| S:1257 E:1259 ||| CD
month  ||| S:1259 E:1265 ||| NN
after  ||| S:1265 E:1271 ||| IN
primary  ||| S:1271 E:1279 ||| JJ
PCI  ||| S:1279 E:1283 ||| NN
in  ||| S:1283 E:1286 ||| IN
IPC  ||| S:1286 E:1290 ||| NNP
group  ||| S:1290 E:1296 ||| NN
was  ||| S:1296 E:1300 ||| VBD
less  ||| S:1300 E:1305 ||| JJR
than  ||| S:1305 E:1310 ||| IN
that  ||| S:1310 E:1315 ||| DT
in  ||| S:1315 E:1318 ||| IN
the  ||| S:1318 E:1322 ||| DT
control  ||| S:1322 E:1330 ||| NN
group  ||| S:1330 E:1336 ||| NN
( ||| S:1336 E:1337 ||| -LRB-
P  ||| S:1337 E:1339 ||| NN
=  ||| S:1339 E:1341 ||| SYM
0.04 ||| S:1341 E:1345 ||| CD
) ||| S:1345 E:1346 ||| -RRB-
.  ||| S:1346 E:1348 ||| .
No  ||| S:1348 E:1351 ||| DT
significant  ||| S:1351 E:1363 ||| JJ
benefit  ||| S:1363 E:1371 ||| NN
of  ||| S:1371 E:1374 ||| IN
IPC  ||| S:1374 E:1378 ||| NNP
for  ||| S:1378 E:1382 ||| IN
reduction  ||| S:1382 E:1392 ||| NN
of  ||| S:1392 E:1395 ||| IN
myocardial  ||| S:1395 E:1406 ||| JJ
infarct  ||| S:1406 E:1414 ||| JJ
size  ||| S:1414 E:1419 ||| NN
as  ||| S:1419 E:1422 ||| IN
determined  ||| S:1422 E:1433 ||| VBN
by  ||| S:1433 E:1436 ||| IN
peak  ||| S:1436 E:1441 ||| JJ
creatine  ||| S:1441 E:1450 ||| JJ
kinase  ||| S:1450 E:1457 ||| NN
and  ||| S:1457 E:1461 ||| CC
CK-MB  ||| S:1461 E:1467 ||| JJ
release ||| S:1467 E:1474 ||| NN
,  ||| S:1474 E:1476 ||| ,
as  ||| S:1476 E:1479 ||| RB
well  ||| S:1479 E:1484 ||| RB
as  ||| S:1484 E:1487 ||| IN
LVEF ||| S:1487 E:1491 ||| NNP
.  ||| S:1491 E:1493 ||| .
The  ||| S:1493 E:1497 ||| DT
incidence  ||| S:1497 E:1507 ||| NN
of  ||| S:1507 E:1510 ||| IN
MACE  ||| S:1510 E:1515 ||| NNP
was  ||| S:1515 E:1519 ||| VBD
improved  ||| S:1519 E:1528 ||| VBN
in  ||| S:1528 E:1531 ||| IN
patients  ||| S:1531 E:1540 ||| NNS
who  ||| S:1540 E:1544 ||| WP
received  ||| S:1544 E:1553 ||| VBD
IPC ||| S:1553 E:1556 ||| NNP
.  ||| S:1556 E:1558 ||| .
